Drug pricing has been the subject of Congressional inquiries, government investigations, and media attention. Generic drugs have long played an important role in reducing drug prices. Has the recent wave of generic drug company consolidation adversely affected pricing? Are overlap divestitures sufficient? Are prices being fixed, as might be suggested by DOJ’s criminal investigation and related civil litigation? Steven Tenn is a panelist on this topic.
For more information on this event, click here.
IP Literature Watch: May 2025
We are pleased to present the latest edition of CRA’s IP Literature Watch. This issue contains pieces on antitrust & IP, licensing, litigation, innovation, law...